You just read:

Hillhurst Biopharmaceuticals Receives SBIR Funding For Development Of HBI-002 For Prevention Of Delayed Graft Function In Kidney Transplantation

News provided by

Hillhurst Biopharmaceuticals, Inc.

Jun 14, 2017, 14:34 ET